Policy & Regulation
Bicycle Therapeutics prices upsized public offering at USD54.00 per ADS
14 October 2021 -

Biotechnology company Bicycle Therapeutics plc (Nasdaq:BCYC) said on Wednesday that it has priced its higher underwritten public offering of 3,240,741 American Depositary Shares (ADSs) at USD54.00 per ADS for gross proceeds of USD175.0m.

Each ADS reportedly represent one ordinary share in the company.

The company has provided the underwriters in the offering with 30-day option to purchase up to another 486,111 ADSs at the public offering price.

Net proceeds may be used by the company to advance its proprietary product pipeline as well as for research and development and general corporate purposes.

For the offering, Goldman Sachs & Co. LLC, Morgan Stanley and SVB Leerink are acting as joint book-running managers. JMP Securities is acting as co-manager. The offering is expected to close on or about 15 October 2021, subject to customary closing conditions.



Related Headlines